Latest news about Albert David
UK Government Appoints David Reed as Trade Commissioner for Eastern Europe
Albert David
720.85
+16.95(+2.41%)
Company Performance:
View Company Insights1D+2.41%
1M+0.22%
6M-11.41%
1Y-12.72%
5Y+63.79%
More news about Albert David
10Mar 26
Albert David Limited Announces Resignation of International Business Leader
Albert David Limited announced the resignation of Mr. Thakkar Rushabh Kishorbhai, International Business Leader, effective March 27, 2026. The resignation was attributed to a better job opportunity, and the company has acknowledged his contributions during his tenure with the organization.
19Dec 25
Albert David MD & CEO Umesh Kunte Resigns Due to Personal Priorities
Albert David Limited's Managing Director and CEO Umesh Manohar Kunte has resigned from all his positions effective December 18, 2025, citing personal reasons and priorities. The Board accepted his resignation during a meeting held on the same day, with the company expressing appreciation for his contributions and services during his tenure with the pharmaceutical manufacturer.
12Nov 25
Albert David Limited Reports Q2 FY26 Results: Revenue Declines, Net Loss Narrows
Albert David Limited, a pharmaceutical manufacturer, released its Q2 FY26 results. Revenue decreased to Rs. 5,857.00 lakhs from Rs. 7,056.64 lakhs in Q1. Net loss reduced to Rs. 540.04 lakhs from Rs. 779.76 lakhs. H1 FY26 revenue totaled Rs. 13,779.18 lakhs with a net loss of Rs. 526.71 lakhs. The company paid a Rs. 5.00 per share dividend. Total assets increased to Rs. 53,294.06 lakhs, and total equity rose slightly to Rs. 39,389.66 lakhs. The company faced operational cash flow challenges but saw positive financing cash flow.
17Sept 25
Albert David Shareholders Approve Dr. Rajiv Anant Desai's Appointment as Independent Director
Albert David, a pharmaceutical company, has appointed Dr. Rajiv Anant Desai as an Independent Director for a five-year term from August 2, 2025, to August 1, 2030. The appointment was approved through a postal ballot with 99.99% of votes in favor. Dr. Desai, with over 38 years of experience in the pharmaceutical industry, holds a Ph.D. in Pharmaceutical Chemistry and an MBA. He previously served as Executive Vice President at Lupin Limited and currently works as a Senior Technical Advisor with the Indian Pharmaceutical Alliance.
04Aug 25
Albert David Limited Reports Mixed Q1 FY2026 Results with Decline in Revenue and Profit
Albert David, a pharmaceutical company, released Q1 FY2026 results showing a 21% year-on-year revenue decline to Rs. 7,056.64 lakhs. Net profit fell 58% to Rs. 793.76 lakhs. EPS decreased to Rs. 13.91 from Rs. 33.02 in Q1 FY2025. The company's equity share capital remained unchanged at Rs. 570.72 lakhs. The results were approved by the board on August 2, 2025, after a limited review by statutory auditors.
02Aug 25
Albert David Limited Appoints Pharma Veteran as New Independent Director, Approves Q1 Results
Albert David Limited's board approved Q1 financial results for the quarter ended June 30, 2025. The company appointed Dr. Rajiv Anant Desai as an Additional Non-Executive Independent Director, effective August 2, 2025, subject to shareholder approval via postal ballot. Dr. Desai, 63, brings 38 years of pharmaceutical industry experience, including roles at Lupin Limited and Indian Pharmaceutical Alliance. His appointment is for a five-year term.
02Aug 25
Albert David Reports 59% Decline in Q1 Net Profit, Appoints New Independent Director
Albert David Limited's Q1 net profit declined by 59.30% to ₹77.50 million from ₹190.40 million year-over-year. The Board approved Q1 financial results and appointed Dr. Rajiv Anant Desai as Additional Non-Executive Independent Director for five years, effective August 2, subject to shareholder approval. Dr. Desai brings 38 years of pharmaceutical industry experience, including roles at Indian Pharmaceutical Alliance and Lupin Limited.
13May 25
Albert David Ltd Reports Q4 FY23 Results: EBITDA Loss Widens, Revenue Declines; Recommends Dividend
Albert David Ltd's Q4 FY23 results show a 15.94% YoY revenue decline to ₹749.00 crore. EBITDA swung to a loss of ₹48.00 crore from a profit of ₹96.00 crore in Q4 FY22. Net loss improved by 20.16% YoY to ₹103.00 crore. The company recommended a dividend of ₹5 per equity share despite financial challenges.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Lupin
Mankind Pharma
Zydus Life Science
Aurobindo Pharma
Laurus Labs
1,878.20
(+0.81%)
6,760.50
(-2.33%)
4,405.70
(+0.04%)
1,432.10
(-0.32%)
1,336.70
(+2.54%)
2,276.20
(+0.80%)
2,503.00
(+1.66%)
1,011.70
(+2.02%)
1,511.80
(+0.06%)
1,323.60
(+0.62%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
